A phase 2b, randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of two doses of NGM282 administered for 24 weeks for the treatment of histologically confirmed Non-alcoholic Steatohepatitis (NASH).
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.